Swipe to navigate
Build the wedge. Earn the platform.
ABx is building a sequenced applied-biology company with a clearly bounded first market. Mino is the initial commercial wedge: premium companion-animal offerings organized around defined product boundaries, disciplined delivery, and a customer category with adjacent demand but no trusted leader. Companion animals come first because that market offers a narrower commercial and regulatory wedge than direct livestock deployment.
If that first wedge validates demand, trust, and regulatory sequencing, the same platform may later support welfare-oriented applications in livestock. The argument of this deck is therefore sequential rather than speculative: establish a credible entry point first, then evaluate broader welfare applications on stronger technical and institutional footing.1, 2, 4, 6, 7, 22
Gene editing has already moved from basic research into regulated commercial use in animals and medicine.6, 7, 22 Yet companion animals still have no trusted category owner even though adjacent buyers already pay for cloning, selective breeding, and specialty care inside a $158B U.S. pet market.16, 18, 21
ABx starts with that narrower commercial gap. The broader welfare thesis matters because more than 90 billion land animals are slaughtered each year for food,19 most in intensive systems,20 but the first market still has to be built where demand, trust, and regulation are easiest to sequence.
A companion-animal business can finance a broader welfare platform.
ABx operates through two linked programs. Mino is the near-term commercial wedge: premium companion-animal offerings where consumers already pay for bespoke biology through cloning, selective breeding, and specialty care.18, 21 The longer-horizon program applies the same technical platform to pain-pathway modification in livestock.5, 9 The relationship is practical rather than rhetorical: the companion market can produce revenue, regulatory experience, and genotype-to-phenotype data that de-risk a larger welfare agenda.
Large-capital biology platforms validate investor appetite for ambitious biotech. None is organized around this market sequence.
Specified before they exist.
Mino is the first public commercial wedge. Initial commercialization focuses on premium, high-trust traits that can be described clearly to customers and eventually defended to regulators: coat, size, temperament, allergen profile, and longevity. The longer design space is broader, but the first market does not require maximal novelty; it requires credible delivery.
FDA-approved gene-edited pig. Alpha-gal sugar knocked out via intentional genomic alteration. Approved for both food and potential xenotransplantation use. December 2020.6
FDA, Revivicor / United TherapeuticsHeat-tolerant cattle produced via CRISPR modification of the prolactin receptor gene. FDA enforcement discretion granted March 2022 — the first for gene-edited livestock.7
FDA, Acceligen / RecombineticsAlphaFold DB v6 now contains more than 241 million predicted protein structures, and AlphaFold 3 extended prediction from proteins alone to protein, DNA, RNA, ligand, and complex interactions in 2024.4
EMBL-EBI / Google DeepMindNHGRI's long-run sequencing-cost series shows a multi-order-of-magnitude drop since 2001, with the curve breaking sharply away from Moore's law once next-generation sequencing arrived in 2008.3
NHGRIMassachusetts General Hospital performed the world's first gene-edited pig kidney transplant into a living human in March 2024 and a second living-recipient kidney xenotransplant in January 2025.8
MGH / Mass General BrighamCasgevy became the first FDA-approved therapy to use CRISPR/Cas9 in December 2023, making genome editing a regulated therapeutic reality rather than a research-only technique.22
FDA / Vertex / CRISPR TherapeuticsNHGRI's benchmark shows genome sequencing costs outpaced Moore's law after 2008 and have stayed on a sharply downward curve ever since.3
NHGRIAlphaFold DB v6 has moved structural lookup from scarcity to abundance, with more than 241 million predicted protein structures now openly available.4
EMBL-EBI / DeepMindThe first FDA-approved CRISPR/Cas9 therapy arrived in December 2023. Editing has now crossed from platform promise into commercial medicine.22
FDANo scaled company has yet defined the product boundaries, trust model, and regulatory sequencing for a companion-animal wedge. The capability stack exists, but the category still has to be earned.
Commercial landscape review
Customer requests are screened for biological plausibility, welfare constraints, and regulatory tractability. The early product is a constrained design brief, not unrestricted trait selection.
Programs advance only through a narrow intervention plan, full quality control, and welfare review before any case moves forward.1 The operational discipline is closer to regulated biotech than luxury breeding.
Licensed partner facilities handle gestation, veterinary oversight, and delivery. ABx retains the genomic workflow, post-delivery monitoring, and the outcome dataset that improves future programs.
ABx does not need global approval to prove the category. The first job is to launch where premium demand, veterinary mediation, and regulatory legibility overlap tightly enough to create first precedent.
Japan already offers a notification path for gene-edited products. Japan, Singapore, and South Korea create the cleanest first-adopter wedge for a tightly scoped premium launch.
The GCC already supports concierge veterinary care and status-linked companion spending. This is a premium trust market, not a mass-market pet channel.
Europe is slower, but welfare framing may resonate more clearly there than in a pure consumer-biotech pitch. One approval can still create a multi-country signal.
Launch rule: establish one reference market, then compound from precedent.
Sources 14, 15, 16, 18
ABx is not underwriting all pets. It is targeting a premium, high-trust segment inside a category where owners already pay emotionally, repeatedly, and at luxury-biotech price points.
U.S. pet spend reached $152B in 2024 across a 94M-household ownership base. ABx only needs a narrow premium segment inside that installed demand.
Pet cloning already proves that a subset of owners will pay biotech prices for identity-linked outcomes and continuity.
No scaled company has set the product boundaries, launch sequence, or customer expectations for companion genomics.
ABx does not need mainstream adoption. It needs the first premium trust model.
Sources 16, 18, 21
Incumbents validate capital appetite, technical infrastructure, or buyer willingness to pay. None define a companion-animal wedge with defined product boundaries and a welfare-aware frame.
Biology is already funded.
Luxury spend in pets is already proven.
Category ownership is still open.
Owns the public wedge, defined offer, and welfare-aware category frame.
No other company combines all three.
Shows that owners already pay biotech prices for identity and continuity.
Does not own trait design, category rules, or a welfare mandate.
Proves platform-level biology infrastructure can attract capital and enterprise demand.
Not a consumer animal category and not a trust brand.
Shows that animal genetics can become a serious commercial operating system.
No premium pet wedge, no consumer surface, no welfare narrative.
Large-scale biotech storytelling can pull attention and capital into frontier biology.
Not a companion-animal commercialization sequence.
Source anchor 18
Set the acceptable trait set, language, and care model first.
Later entrants inherit the frame.
One recognized path becomes the benchmark for later review.
Later filings cite the first win.
Each delivery sharpens genotype-to-phenotype screening.
Design quality improves with use.
Explicit rules make the category legible to buyers and regulators.
Trust compounds only with limits.
ABx wins by becoming the reference system, not by running a louder marketing race.
Each layer activates after a narrower hurdle is cleared. The model is sequential by design: prove trust, then unlock higher-value revenue.
Qualified deposits only after delivery timing becomes credible.
Gate: signal quality + timing proof.
Initial commercial delivery in a tightly scoped premium market.
Gate: regulatory path + partner-lab readiness.
Monitoring, health data, and lifetime service attached to the animal.
Gate: first animals in market.
Protocol licensing and facility partners once the playbook is repeatable.
Gate: validated operating system.
ABx is pre-revenue and pre-lab by design. The present job is to collect demand, regulatory, and hiring signals before capital is deployed into scientific execution.
Mino is public and already capturing language, buyer, and interest-quality signals ahead of commercialization.
Relevant animal-editing precedents are already sequenced into a multi-jurisdiction launch thesis.
Sources 6, 7, 14, 15, 23
Early conversations are underway with gene-editing and animal-genomics operators who can own quality thresholds.
Pricing, objections, and psychographic fit are being tested through waitlist behavior and direct outreach.
Each milestone narrows risk before the next one opens. The roadmap is built to create precedent, not to simulate scale too early.
Recruit scientific and regulatory leadership and lock the first lab plan.
Run early editing workflows through partner facilities and build the first safety dataset.
Advance tightly scoped dossiers and turn qualified demand into a regulated pipeline.
Execute the first commercial deliveries in a narrow reference market with veterinary oversight.
Deepen the genotype-to-phenotype layer and widen the operating network.
Open only after the companion-animal platform has earned technical and regulatory credibility.
Livestock work remains downstream of companion proof.
The commercial thesis stands on companion animals first. The livestock program matters later because one narrow pain pathway already has a coherent mechanistic literature.
Loss-of-function evidence links the channel directly to pain signalling, making the biology unusually legible.
The affective component of pain can be reasoned about separately from protective reflexes.
This is narrower and more mechanistically legible than most animal-welfare ideas, even if translation remains far away.
The ethical case is mature. The governed commercialization path still does not exist.
Sources 5, 9, 10, 11, 12
The raise does not fund a sprawling org chart. It installs the minimum leadership needed to turn a category thesis into governed execution.
Define the first market, product boundaries, and launch sequence for a category with no standard template.
Run the seed process, refine the waitlist and product brief, and recruit scientific ownership early.
Scientific leadership, regulatory ownership, partner-lab capacity, and the first governed validation data.
Founder role
Category design, capital formation, product framing, and early sequencing across research, brand, and launch.
Open role · Scientific co-founder
Deep gene-editing or animal-genomics operator who can own experimental design, quality thresholds, and partner-lab decisions.
Open role · Regulatory lead
FDA CVM or comparable animal-biotech operator who can own sequencing, dossier strategy, and jurisdiction design.
$12M
Seed Round · 2026
ABx is raising $12M to recruit the scientific and regulatory core team, secure BSL-2+ lab capacity, generate initial validation data, and advance the first jurisdictional submissions. The near-term objective is not global scale; it is early precedent in a category that still has no established leader. Capital is therefore being applied to the team and the first regulated proof points, rather than to premature scale.
